cIAP1 Ligand-Linker Conjugates 9 are specialized chemical compounds designed for research and development in the field of targeted protein degradation, particularly within the PROTAC (Proteolysis Targeting Chimera) platform. As E3 Ligase Ligand-Linker Conjugates, these molecules combine a high-affinity ligand for the cIAP1 E3 ubiquitin ligase with a customizable linker, facilitating the creation of bifunctional degraders. In PROTAC technology, these conjugates enable the recruitment of cIAP1 to target proteins of interest, leading to their ubiquitination and subsequent proteasomal degradation. This innovative mechanism is widely used in drug discovery, cell biology, and therapeutic research to selectively knock down disease-associated proteins, including those considered 'undruggable' by traditional approaches. With optimized linker chemistry and high specificity for cIAP1, these conjugates provide a robust starting point for developing novel therapeutic agents and studying protein function in cellular systems.
Quality Assurance
Worldwide Delivery
24/7 Customer Support
Category
E3 Ligase Ligand-Linker Conjugate
Molecular Formula
C37H48N4O7
Molecular Weight
660.8
* For research and manufacturing use only. Not for human or clinical use.
Size
Price
Stock
Quantity
--
$--
In stock
Looking for different specifications? Click to request a custom quote!
cIAP1 Ligand-Linker Conjugates 9 are specialized chemical tools designed for targeted protein degradation. These compounds are engineered by linking a small molecule ligand, specifically targeting cIAP1 (cellular Inhibitor of Apoptosis Protein 1), to a linker structure. This modular architecture enables the construction of next-generation PROTACs and molecular glues, advancing drug discovery efforts, particularly in oncology and disease areas involving dysregulated protein homeostasis.
Mechanism
cIAP1 Ligand-Linker Conjugates 9 operate as bifunctional molecules in the design of PROTACs (Proteolysis Targeting Chimeras). The conjugate contains a ligand that selectively binds to cIAP1, an E3 ubiquitin ligase enzyme, tethered via an optimized linker. When further connected to a target protein ligand, this structure brings the target protein into close proximity with cIAP1, facilitating ubiquitination and subsequent degradation by the proteasome. This mechanism allows for precise and efficient removal of pathogenic proteins inside cells.
Applications
cIAP1 Ligand-Linker Conjugates 9 are widely utilized in the development of PROTACs for targeted protein degradation research. They serve as a critical building block to generate PROTAC molecules tailored for degrading disease-relevant proteins, especially in cancer research and neurodegenerative disease studies. Additionally, these conjugates are instrumental in the validation of novel E3 ligase-recruiting strategies, mechanistic studies of ubiquitin-proteasome system modulation, and the screening of potential therapeutic candidates in preclinical and drug discovery pipelines.
• Specifically designed for efficient cIAP1 E3 ligase recruitment in PROTAC applications, enhancing target protein degradation.
• Incorporates a versatile linker for straightforward conjugation with a wide range of target ligands, enabling customizable PROTAC synthesis.
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
Cat No.: BP-100092
